Athena Cherry

Member, Stanford Cancer Institute

Academic Appointments

Member, Stanford Cancer Institute

Professional Education

Ph.D., Indiana University, Medical Genetics (1990)

Current Research and Scholarly Interests

The use of molecular and molecular cytogenetic methods to identify chromosomal abnormalities in acquired and congenital disorders.

Clinical Trials

Phase 2 Fludarabine, Cytoxan and FCCAM <Alemtuzumab> in Untreated B-Cell Chronic Lymphocytic Leukemia Not Recruiting
More
The primary objective of this study was to evaluate the safety and efficacy of the combination of fludarabine and cyclophosphamide in previously untreated CLL patients. Participants will receive fludarabine and cyclophosphamide on days 1, 2, and 3 of six 28-day cycles.

Stanford is currently not accepting patients for this trial. For more information, please contact Nini Estevez, 6507254041.
Lead Sponsor
Stanford Investigators
View full details

2022-23 Courses

Independent Studies
- Directed Reading in Pathology
  PATH 299 (Aut, Win, Spr, Sum)
- Early Clinical Experience in Pathology
  PATH 280 (Aut, Win, Spr, Sum)
- Graduate Research
  PATH 399 (Aut, Win, Spr, Sum)
- Medical Scholars Research
  PATH 370 (Aut, Win, Spr, Sum)
- Undergraduate Research
  PATH 199 (Aut, Win, Spr, Sum)

Graduate and Fellowship Programs

Genetics (Phd Program)

All Publications